Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins
DOI:
https://doi.org/10.15381/anales.v68i2.1228Keywords:
Spondylitis, ankylosing, antirheumatic agents, rheumatic diseasesAbstract
Infliximab is effective in treating patients with ankylosing spondylitis (AS). However, its cost makes its indiscrimate use prohibitive. Objective: To determine whether an induction regimen with infliximab remained effective over time in a group of patients with active AS. Design: Exposed only. Setting: Rheumatology Service, Hospital Nacional Edgardo Rebagliati. Participants: Patients with active and refractory ankylosing spondylitis. Interventions: Infliximab, administered at weeks 0, 2 and 6. One patient received doses of 3 mg/kg and the remaining patients received 5 mg/kg of infliximab. All patients continued their treatment with sulfasalazine. Main outcome measures: We determined the proportion of patients achieving ASAS 20, ASAS 40 and Bath ankylosing spondylitis disease activity index - BASDAI 50 at last assessment (median of 55 weeks). Results: At last observation, five patients (71,4%) had a sustained ASAS 20 response. Four (57%) and three (43%) patients remained responders according to the BASDAI 50 and ASAS 40 respectively.Three patients (43%) relapsed, with mean time of 26,6 weeks. No serious adverse events were observed. Conclusions: The infusion of three doses of infliximab is effective to control disease activity in patients with refractory AS. In some patients, effectiveness remained for a prolonged period of time.Downloads
Published
2007-06-18
Issue
Section
Original Breve
License
Copyright (c) 2007 Manuel Montero, Augusto García-Poma, Cecilia Chung, José Chávez, María I. Segami
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Those authors who have publications with this magazine accept the following terms:
- Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
- Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
- Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).
How to Cite
1.
Montero M, García-Poma A, Chung C, Chávez J, Segami MI. Infliximab in patients with active ankylosing spondylitis: experience at Hospital Nacional Edgardo Rebagliati Martins. An Fac med [Internet]. 2007 Jun. 18 [cited 2024 Jul. 3];68(2):175-80. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1228